Media Newsroom of

Syndivia

650 Boulevard Gonthier d'Andernach
Illkirch-Graffenstaden, Grand Est 67400
Syndivia

Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment of RAS-mutated and solid tumours.

Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est

Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est

Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, announced today that it has been granted an exclusive, worldwide sublicense by SATT Sud-Est…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login